

Research

Open Access

Attributable mortality of *Acinetobacter baumannii* infections in critically ill patients: a systematic review of matched cohort and case-control studiesMatthew E Falagas^{1,2}, Ioannis A Bliziotis¹ and Ilias I Siempos¹¹Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Greece²Department of Medicine, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USACorresponding author: Matthew E Falagas, m.falagas@aibs.gr

Received: 16 Jan 2006 Revisions requested: 16 Feb 2006 Revisions received: 23 Feb 2006 Accepted: 27 Feb 2006 Published: 21 Mar 2006

Critical Care 2006, **10**:R48 (doi:10.1186/cc4869)This article is online at: <http://ccforum.com/content/10/2/R48>© 2006 Falagas *et al.*; licensee BioMed Central Ltd.This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.**Abstract**

Introduction There has been a continuing controversy about whether infection with *Acinetobacter baumannii* increases morbidity and mortality independently of the effect of other confounding factors.

Methods We performed a systematic review of matched case-control and cohort studies examining the mortality attributable to infection with or acquisition of *A. baumannii* (infection or colonization). We included in our review studies that compared mortality and/or morbidity of patients with acquisition of or infection with *A. baumannii* (cases) with the outcomes of matched patients without *A. baumannii* isolation from clinical specimens (controls). The relevant studies were identified from searches of the PubMed and the Cochrane Library databases. Two independent reviewers performed the literature search, study selection, and data extraction from nine identified relevant studies.

Results The attributable mortalities, in the hospital and in the intensive care unit, of patients with *A. baumannii* infection in six matched case-control studies included in our review ranged from 7.8% to 23% and from 10% to 43%, respectively. In addition, a statistically significantly higher mortality was reported for patients with *A. baumannii* acquisition; that is, colonization or infection (cases) compared with controls without such an acquisition in all four reviewed studies that reported data on this comparison.

Conclusion Although definitive statements about the mortality attributable to the acquisition of *A. baumannii* cannot be made from the available studies because of their methodological heterogeneity, the reviewed data suggest that infection with or acquisition of *A. baumannii* seems to be associated with increased mortality.

Introduction


Acinetobacter baumannii is a ubiquitous, non-fermenting, aerobic Gram-negative bacterium with intrinsic resistance to multiple antimicrobial agents [1,2]. During the past few decades the organism has emerged as an important nosocomial pathogen, affecting mainly severely ill patients in the intensive care unit (ICU) setting worldwide. *A. baumannii* has been recognized as a leading cause of nosocomial pneumonia and bacteremia (related to central venous catheters or not) in several hospitals in various parts of the world [3-6].

However, there has been a continuing controversy over whether colonization - and, even more importantly, infection - with *A. baumannii* increase morbidity and mortality independ-

ently of the effect of other confounding factors. Although several investigators provided evidence that *A. baumannii* infections may be associated with considerable mortality [7-10], some of them support the possibility that the clinical course of critically ill patients may be influenced by many variables and that subsequently the acquisition of or infection with *A. baumannii* may not independently lead to poorer outcomes [11-13]. This controversy has caused considerable confusion among clinicians and investigators about the mortality associated with *A. baumannii* infections. We therefore sought to systematically identify and synthesize the available evidence about the mortality attributable to acquisition of or infection with *A. baumannii* in critically ill patients by retrieving the available data from relevant matched case-control studies.

ICU = intensive care unit; VAP = ventilator-associated pneumonia.

Figure 1



Flow diagram of reviewed articles.

Materials and methods

Search strategy

Two independent reviewers (IAB and IIS) performed the literature search, study selection, and data extraction. Any disagreement between the two reviewers was resolved by consensus in meetings of all authors. We searched for studies indexed in the PubMed and Cochrane Library (part of which is also the Cochrane Central Register of Controlled Trials) databases by using the following key terms: '*Acinetobacter*', 'mor-

tality', 'colonization', 'case-control', 'match', 'length of stay', and/or 'ICU'. No limits were set in our literature search about the time or language of publication. The references from the identified articles were also searched for relevant publications.

Study selection

Studies included in our systematic review were case-control or matched cohort studies that compared mortality and/or morbidity of patients with acquisition of or infection with

Table 1

Characteristics and outcomes of matched cases and controls (patients infected and non-infected with *A. baumannii*)

Reference	Site of infection; patients and setting	Cases	Controls	Matching of controls to cases	Mortality				Length of ICU stay (days)		
					Cases	Controls	<i>p</i>	Attributable mortality (%)	Cases	Controls	<i>p</i>
[14]	Bacteremia; medical, surgical, burn, and cardiac surgery ICUs of a hospital in Belgium	45 patients with <i>Ab</i> bacteremia	90 patients without bacteremia (excluding coagulase-negative <i>Staphylococci</i>)	(1) APACHE II score; (2) primary diagnosis of ICU admission; (3) LOS in the ICU at least as long as that of the case prior to isolation of <i>Ab</i>	Hospital: 19/45 (42.2%)	Hospital: 31/90 (34.4%)	0.378	7.8 (95% CI - 9.7 to 25.3)	Mean 28, SD 19.9, median 25, IQR 16–34	Mean 23, SD 20.2, median 20, IQR 8–31	0.043
					ICU: 14/45 (31.3%)	ICU: 19/90 (21.3%)	0.203	10			
[18]	Bloodstream infection; burn ICU in Germany	29 patients with nosocomial <i>Ab</i> bloodstream infection	58 matched controls without <i>Ab</i> BSI	(1) Date of admission; (2) age; (3) LOS in the ICU at least as long as that of the case before isolation of <i>Ab</i> ; (4) same unit	Hospital: 9/29 (31%)	Hospital: 8/58 (14%)	0.056	17	Mean 50, SD 27	Mean 30, SD 23	NR
[11]	Microbiologically documented VAP; 4 Spanish ICUs	60 patients with VAP due to <i>Ab</i>	60 patients with any documented non- <i>Ab</i> infection or no infection at all	(1) Equal or longer duration of stay in ICU before pneumonia; (2) APACHE II score; (3) primary diagnosis of ICU admission	ICU: 24/60 (40%)	ICU: 17/60 (28.3%)	0.17	11.7	Mean 35.3, SD 23.8	Mean 36.6, SD 35.7	NS
[15]	Nosocomial outbreak of resistant <i>Ab</i> ; MICU in USA	14 patients with <i>Ab</i> nosocomial pneumonia and/or bloodstream infection	29 patients mechanically ventilated for at least 7 days without developing <i>Ab</i> infection or colonization	(1) Date of admission; (2) mechanical ventilation in the MICU for ≥ 1 week	Hospital: 6/14 (43%)	Hospital: 11/29 (32%)	0.9	11	NR	NR	NR
[21]	Acquisition of <i>Ab</i> in critically ill patients in ICU; medical and surgical ICU in Spain	75 patients (48 infected, 27 colonized) with <i>Ab</i> isolation	75 patients without any <i>Ab</i> isolation	(1) Age; (2) sex; (3) APACHE II; (4) date of admission; (5) primary diagnosis of ICU admission; (6) LOS in the ICU at least as long as that of the case before isolation of <i>Ab</i> ; (7) Mechanical ventilation for >24 h	ICU: 28/48 (58%)	ICU: 7/48 (15%)	< 0.001	43 (95% CI 34–52)	Mean 30.1, SD 27.2, median 23, IQR 11.5–37	Mean 15.5, SD 19.3, median 10, IQR 7.5–15	< 0.001
[20]	Nosocomial acquisition of MDR <i>Ab</i> ; MICU in France	40 patients (13 infected and 27 colonized) with <i>Ab</i>	40 patients non-infected and non-colonized with <i>Ab</i>	(1) APACHE II score; (2) LOS in the ICU at least as long as that of the case before isolation of <i>Ab</i> ; (3) age; (4) date of admission	Hospital: 7/13 (53.8%)	Hospital: 4/13 (30.8%)	0.23	23	Mean 23.8, SD 9.6	NR	NR
[17]	Colonization or infection with (89% MDR) <i>Ab</i> ; trauma centre in USA. Most patients were in ICUs	102 patients (33 infected, 69 colonized) with <i>Ab</i>	102 controls without <i>Ab</i>	(1) Primary diagnosis (computerized codes); (2) same period	Hospital: 14/33 (42%)	NR	NA	NA	Mean 51.33, SD 6.79	Mean 19.00, SD 5.90	< 0.001

Ab, *Acinetobacter baumannii*; APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; ICU, intensive care unit; IQR, interquartile range; LOS, length of stay; MDR, multidrug resistant; MICU, medical ICU; NA, non-applicable; NR, not reported; NS, non-significant; VAP, ventilator-associated pneumonia.

Table 2**Comparison of patients with acquisition of *A. baumannii* with matched controls**

Reference	Site of infection; patients and setting	Cases	Controls	Matching of controls to cases	Colonization or infection				Length of ICU stay (days)		
					Mortality		<i>p</i>	Attributable mortality (%)	Cases	Controls	<i>p</i>
[21]	Acquisition of <i>Ab</i> in critically ill patients in ICU; medical and surgical ICU in Spain	75 patients (48 infected and 27 colonized) with <i>Ab</i>	75 patients without any <i>Ab</i> isolation	(1) Age (\pm 6 years); (2) sex; (3) APACHE II; (4) date of admission; (5) primary diagnosis of ICU admission; (6) LOS in the ICU at least as long as that of the case before isolation of <i>Ab</i> ; (7) Mechanical ventilation for >24 h	ICU: 37/75 (49%)	ICU: 14/75 (19%)			< 0.001	30 (95% CI 23–37)	Mean 30.7, SD 26.9, median 23, IQR 11–37
[20]	Nosocomial acquisition of MDR <i>Ab</i> ; MICU in France	40 patients (13 infected and 27 colonized) with <i>Ab</i>	40 patients without any <i>Ab</i> isolation	(1) APACHE II score; (2) LOS in the ICU at least as long as that of the case before isolation of <i>Ab</i> ; (3) age; (4) date of admission	Hospital: 20/40 (50%)	Hospital: 10/40 (25%)	0.046	25	Mean 22.6, SD 9.6, median 19, IQR 5–82	Mean 12.3, SD 12.9, median 11, IQR 3–35	< 0.001
[16]	Nosocomial outbreak of MDR <i>Ab</i> ; ICU in USA	25 patients (9 infected, 15 colonized) with <i>Ab</i>	32 patients with cultures negative for <i>Ab</i>	(1) Same ICU; (2) date of admission	Hospital: 13/25 (52%)	Hospital: 8/32 (25%)	0.036	27	Mean 19.6, median 18	Mean 6.1, median 4.5	< 0.05
[17]	Colonization or infection due to (89% MDR) <i>Ab</i> ; trauma centre in USA. Most patients were in medical, surgical, and burns ICUs	102 patients (33 infected, 69 colonized) with <i>Ab</i>	102 controls without <i>Ab</i>	(1) Primary diagnosis (computerized codes); (2) same period	Hospital: 35/102 (34%)	Hospital: 18/102 (18%)	0.007	16	Mean 27.35, SD 28.21	Mean 5.53, SD 15.87	< 0.001
[19]	Colonization or infection due to <i>Ab</i> ; university hospital in France. 52% of the patients were hospitalized in an ICU	121 patients (infected or colonized) with <i>Ab</i>	121 patients with the same specimen as cases found negative for <i>Ab</i>	(1) Same unit; (2) same period; (3) same type of specimen	NR	NR	NR	NR	Mean 29, SD 20	Mean 13, SD 10	NR

Acquisition of *A. baumannii* is defined as patients colonized or infected with the organism; matched controls were those without acquisition of the organism. *Ab*, *Acinetobacter baumannii*; APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; ICU, intensive care unit; IQR, interquartile range; LOS, length of stay; MDR, multidrug resistant; NR, not reported.

A. baumannii (cases) with the outcomes of matched patients without *A. baumannii* isolation from clinical specimens (controls).

Data extraction

We extracted data about the date, setting, and patient population from the studies selected. In addition, the site of infection, the numbers of cases and controls, the methodology for the matching of controls to cases, and clinical outcomes of interest were extracted.

Outcomes

The main outcomes that we examined in our systematic review were the crude ICU and/or in-hospital mortality of cases and controls, as well as the mortality attributable to acquisition of or infection with *A. baumannii*. The mortality attributable to colonization or infection by *A. baumannii* was determined by subtracting the crude mortality of controls from the crude mortality of cases. In addition, the length of stay in the ICU or in the hospital was reviewed as a secondary outcome.

Results

Selected studies

The steps that we followed to select the relevant studies for our analysis are presented in Figure 1. We initially identified 434 potentially relevant studies from the search of the PubMed and Cochrane Library databases as well as from reading the references of relevant studies. In the end there were nine case-control studies (six retrospective [11,14-18], one prospective [19], and two with mixed, bi-directional study design, in which cases were studied prospectively but controls were identified from retrospective data review [20,21]) that compared outcomes in patients colonized or infected with *A. baumannii* (cases) with those of matched patients from whom *A. baumannii* were not isolated [11,14-21].

We present the main characteristics of the analyzed studies, as well as the outcomes of our interest in cases with *A. baumannii* infection and controls, in Table 1. As shown, the infection sites for the cases with *A. baumannii* infection were the lower respiratory tract (ventilator-associated pneumonia (VAP)) in one study [11] and blood (primary or secondary bacteremia) in another two studies [14,18]. In four of the remaining studies both colonization and infection with *A. baumannii* were described, regardless of the affected site. In the two studies that reported on cases with *A. baumannii* infection in the bloodstream, the controls might have been infected with *A. baumannii* but did not have a bloodstream infection with the pathogen. Data on the characteristics of the studies as well as reported outcomes for patients with acquisition (colonization or infection) of *A. baumannii* and outcomes for controls without *A. baumannii* acquisition are presented in Table 2.

Mortality

Four studies reported data on in-hospital mortality in patients infected with *A. baumannii*, in comparison with controls not infected with the microorganism (Table 1) [11,14,15,18,20,21]. In all four studies there was increased mortality in patients infected with *A. baumannii* in comparison with controls, although the difference was not statistically significant. In one of these studies the mortality difference between the compared groups almost reached statistical significance [18]. The mortality attributable to *A. baumannii* infection in these studies ranged from 7.8% to 23%. In addition, three studies reported data about the mortality of cases and controls in the ICU [11,14,21]. In all three studies mortality in the ICU was higher in patients infected with *A. baumannii* than in controls. In one of these studies the difference in mortality between cases and controls was statistically significant [21]. Attributable mortality in the ICU ranged from 10% to 43% in the reviewed studies.

Four studies reported mortality data in patients with *A. baumannii* acquisition (colonization or infection with *A. baumannii*), in comparison with controls who were not colonized nor infected with *A. baumannii* (Table 1) [16,17,20,21]. In-hospital mortality and mortality in the ICU were reported in three studies [16,17,20] and one study [21] respectively. Interestingly, in all four studies mortality was statistically higher in patients colonized or infected with *A. baumannii* than in controls. The attributable in-hospital mortality of *A. baumannii* infection in the three studies that reported on this outcome ranged from 16% to 27%, whereas in the other study the attributable mortality in the ICU was 30%. It is noteworthy that two of these four studies did not match the patients for disease severity [16,17].

Length of stay in the ICU

Five out of seven studies that reported data on mortality in patients infected with *A. baumannii* (Table 1) also provided data on the length of stay of cases and controls in the ICU [11,14,17,18,21]. In three of these five studies a statistically significant increase in the length of stay in the ICU was reported for the cases with *A. baumannii* infection [14,17,21], whereas in the remaining two studies no significant difference was found in the length of stay in the ICU between cases and controls.

Data on the length of stay of cases and controls in the ICU was reported in all five studies that examined the effect of acquisition (colonization or infection) of *A. baumannii* (Table 2). A statistically significant increase in the length of ICU stay was noted in four of these five studies for patients who were colonized or infected with *A. baumannii* (cases) in comparison with patients from whom this bacterium was not isolated (controls) [16,17,20,21] (no statistical data on the comparison of this outcome in the studied population were reported in the remaining study [19]).

Discussion

The attributable mortalities, in hospital and in the ICU, of patients with *A. baumannii* infection in the reviewed matched case-control and cohort studies ranged from 7.8% to 23% and from 10% to 43%, respectively. It should be emphasized that all studies that examined mortality of patients (cases) with *A. baumannii* acquisition (colonization or infection) compared with controls without such an acquisition found statistically significant differences; that is, higher mortality in cases than in controls, although a causative role for the isolate on the mortality cannot be directly inferred from these data. In addition, no matching of patients and controls for disease severity was made in two of these studies [16,17]. Further, the length of stay in the ICU was found to be statistically significantly increased in patients with *A. baumannii* infection in three of five studies examining this outcome.

The increase in mortality of patients with infection or acquisition of *Acinetobacter* in comparison with matched controls without colonization or infection, noted in the studies included in the systematic review, is supported by evidence provided by several retrospective and prospective cohort studies examining this issue. For example, Kollef and colleagues [22] found that VAP due to non-fermentative Gram-negative pathogens was independently associated with increased mortality in hospital, with an associated mortality rate of 65%. In that study the occurrence of late-onset VAP due to non-fermentative Gram-negative pathogens was the most important predictor of hospital mortality in patients developing VAP (adjusted odds ratio 5.4; 95% confidence interval 2.8 to 10.3; $p = 0.009$).

In addition, Garrouste-Orgeas and colleagues [23], in a 1-year prospective observational survey, evaluated the clinical effect of salivary or rectal carriage of multi-resistant *Acinetobacter baumannii* and/or *Klebsiella pneumoniae* in patients hospitalized in an ICU. Of 265 patients, 88 (33%) developed oropharyngeal and/or rectal carriage. Mortality was significantly greater in the carrier group (43% versus 25%, $p < 0.001$). Stratification of patients showed that, although abnormal carriage was found in the most severely ill patients, it mainly influenced mortality in the less severely ill. Finally, Wisplinghoff and colleagues [24], reported results from the SCOPE (Surveillance and Control of Pathogens of Epidemiologic Importance) project, a prospective study with 49 participating hospitals in the USA. The authors reported that the mortality of patients with 111 bloodstream infections caused by *A. baumannii* was not significantly different from that of 2,952 patients with bloodstream infections due to other Gram-negative pathogens (35/111 patients with *A. baumannii* died (31.5%) compared with 821/2,952 patients with other Gram-negative pathogens (27.9%)). This study provided strong evidence in support of the position that *A. baumannii* bacteremias are as severe as other Gram-negative bacteremias and thus may result in considerable mortality.

Some of the investigators studying patients with *A. baumannii* infections concluded that mortality in these patients was not independently associated with these infections. In two studies by Garnacho-Montero and colleagues [11,25], one of which was included in our review, the authors suggested that VAP due to *A. baumannii* was not associated with a poorer prognosis than other causes of VAP. In addition, Weingarten and colleagues [17], in another study included in our review, suggested that colonization or infection with *A. baumannii* is not associated with increased mortality, but instead that the severity of the illness of cases and controls is the major determinant of mortality. Finally, Sofianou and colleagues [26], in a prospective cohort study examining the incidence, risk factors and pathogens of VAP, concluded that the occurrence of VAP, regardless of the microbiological etiology, was not associated with higher mortality in 198 ICU patients. However, this finding was in disagreement with those from other studies, including that of Fagon and colleagues [10], in which mortality was higher in cases with VAP caused by *A. baumannii* and *P. aeruginosa* than in controls with bronchial colonization with these pathogens.

Although the aforementioned studies attempted to unravel the prognostic importance of colonization or infection with *A. baumannii*, the disagreement between their results create difficulties in deriving definitive conclusions about the severity of disease that results from this organism. The fact that the organism is often resistant to multiple antimicrobial agents, making it difficult to provide appropriate antibiotic therapy, and also the fact that it affects critically ill patients, make the answer of the above question of crucial importance for clinicians worldwide.

Our systematic review has several limitations. First, we selected for inclusion only matched case-control and cohort studies in our attempt to provide data from comparative studies with analytical methodology. However, it should be noted that different matching criteria were used in the studies included in our review and also that some studies did not take into account the severity of disease as a matching criterion. Second, no specific analysis was provided in the reviewed studies about the effect of colonization or infection of *A. baumannii* with various phenotypes (*in vitro* susceptibility pattern to various antibiotics) [27]. Third, we could not pool the data by using the techniques of meta-analysis because there was considerable heterogeneity in the sites of infections, the populations studied, and, most importantly, matching criteria between the studies. However, although no statistically significant differences were found in the comparison of mortality between patients with *Acinetobacter* infection (cases) and controls without such infection it should be noted that this outcome is probably due to the small sample sizes in the studies included in our systematic review. Thus, either more homogeneous data from studies that would allow a meta-analysis or larger studies with enough power could offer a definite answer

to our research question. Last, we did not evaluate the effect of *A. baumannii* infection at various body sites and systems such as pneumonia and bacteremia on mortality.

Conclusion

The evidence from the reviewed matched case-control and cohort studies examining the mortality of patients with colonization or infection with *A. baumannii* suggests that such colonization and infection might be associated with considerably increased mortality. It should be emphasized that to attribute the difference in mortality between cases and controls directly to colonization or infection with *Acinetobacter* (attributable mortality) is more than a simplified approach to this complex issue. This is because the reviewed studies did not and could not match for other factors that might have made important contributions to mortality. Despite these shortcomings, our systematic review lends support to the idea that *A. baumannii* infections are associated with considerable morbidity and mortality, and clinicians should therefore make every effort to combat them.

Key messages

- There has been controversy over whether colonization and infection with *A. baumannii* increase morbidity and mortality independently of other factors.
- The attributable mortality, in hospital and in the ICU, of patients with *A. baumannii* infection in six matched case-control studies included in our review ranged from 7.8% to 23% and from 10% to 43%, respectively.
- Statistically significantly higher mortality was reported for patients with *A. baumannii* acquisition; that is, colonization or infection (cases) compared with controls without such an acquisition in all four reviewed studies that reported data on this comparison.
- Definitive statements cannot be made about the attributable mortality of acquisition of *A. baumannii* from the analysis of the results from the reviewed studies because of their methodological heterogeneity.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MEF had the idea, designed and supervised the study, and is the guarantor. IIS and IAB performed the literature search, identified the relevant studies to be included in the analysis, and extracted the data for the study. MEF and IAB wrote a first version of the manuscript. All authors made substantial revisions of the manuscript and approved its final version.

References

1. Hancock RE: **Resistance mechanisms in *Pseudomonas aeruginosa* and other nonfermentative gram-negative bacteria.** *Clin Infect Dis* 1998, **27**(Suppl 1):S93-S99.
2. Liassine N: **Problems of antibiotic-resistance Gram negative pathogens in the hospital environment. [In French].** *Schweiz Med Wochenschr* 2000, **130**:1930-1936.
3. Gaynes R, Edwards JR: **Overview of nosocomial infections caused by gram-negative bacilli.** *Clin Infect Dis* 2005, **41**:848-854.
4. Kanafani ZA, Kara L, Hayek S, Kanj SS: **Ventilator-associated pneumonia at a tertiary-care center in a developing country: incidence, microbiology, and susceptibility patterns of isolated microorganisms.** *Infect Control Hosp Epidemiol* 2003, **24**:864-869.
5. Paul M, Weinberger M, Siegman-Igra Y, Lazarovitch T, Ostfeld I, Boldur I, Samra Z, Shula H, Carmeli Y, Rubinovitch B, et al.: ***Acinetobacter baumannii*: emergence and spread in Israeli hospitals 1997-2002.** *J Hosp Infect* 2005, **60**:256-260.
6. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: **Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.** *Clin Infect Dis* 2004, **39**:309-317.
7. Boots RJ, Lipman J, Bellomo R, Stephens D, Heller RF: **Disease risk and mortality prediction in intensive care patients with pneumonia. Australian and New Zealand practice in intensive care (ANZPIC II).** *Anaesth Intensive Care* 2005, **33**:101-111.
8. Cisneros JM, Reyes MJ, Pachon J, Becerril B, Caballero FJ, Garcia-Garmendia JL, Ortiz C, Cobacho AR: **Bacteremia due to *Acinetobacter baumannii*: epidemiology, clinical findings, and prognostic features.** *Clin Infect Dis* 1996, **22**:1026-1032.
9. Niederman MS: **Impact of antibiotic resistance on clinical outcomes and the cost of care.** *Crit Care Med* 2001, **29**:N114-N120.
10. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C: **Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay.** *Am J Med* 1993, **94**:281-288.
11. Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J: **Clinical impact of pneumonia caused by *Acinetobacter baumannii* in intubated patients: a matched cohort study.** *Crit Care Med* 2003, **31**:2478-2482.
12. Tilley PA, Roberts FJ: **Bacteremia with *Acinetobacter* species: risk factors and prognosis in different clinical settings.** *Clin Infect Dis* 1994, **18**:896-900.
13. Vidal F, Mensa J, Almela M, Olona M, Martinez JA, Marco F, Lopez MJ, Soriano A, Horcajada JP, Gatell JM, et al.: **Bacteraemia in adults due to glucose non-fermentative Gram-negative bacilli other than *P. aeruginosa*.** *QJM* 2003, **96**:227-234.
14. Blot S, Vandewoude K, Colardyn F: **Nosocomial bacteremia involving *Acinetobacter baumannii* in critically ill patients: a matched cohort study.** *Intensive Care Med* 2003, **29**:471-475.
15. Husni RN, Goldstein LS, Arroliga AC, Hall GS, Fatica C, Stoller JK, Gordon SM: **Risk factors for an outbreak of multi-drug-resistant *Acinetobacter* nosocomial pneumonia among intubated patients.** *Chest* 1999, **115**:1378-1382.
16. Scerpella EG, Wanger AR, Armitage L, Anderlini P, Ericsson CD: **Nosocomial outbreak caused by a multiresistant clone of *Acinetobacter baumannii*: results of the case-control and molecular epidemiologic investigations.** *Infect Control Hosp Epidemiol* 1995, **16**:92-97.
17. Weingarten CM, Rybak MJ, Jahns BE, Stevenson JG, Brown WJ, Levine DP: **Evaluation of *Acinetobacter baumannii* infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital.** *Pharmacotherapy* 1999, **19**:1080-1085.
18. Wisplinghoff H, Perbix W, Seifert H: **Risk factors for nosocomial bloodstream infections due to *Acinetobacter baumannii*: a case-control study of adult burn patients.** *Clin Infect Dis* 1999, **28**:59-66.
19. Mulin B, Talon D, Viel JF, Vincent C, Leprat R, Thouverez M, Michel-Briand Y: **Risk factors for nosocomial colonization with multiresistant *Acinetobacter baumannii*.** *Eur J Clin Microbiol Infect Dis* 1995, **14**:569-576.
20. Lortholary O, Fagon JY, Hoi AB, Slama MA, Pierre J, Giral P, Rosenzweig R, Gutmann L, Safar M, Acar J: **Nosocomial acquisition of multiresistant *Acinetobacter baumannii*: risk factors and prognosis.** *Clin Infect Dis* 1995, **20**:790-796.
21. Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez FJ, Monterrubio-Villar J, Gili-Miner M: **Mortality and the increase in length of stay attributable to the acquisi-**

- tion of *Acinetobacter* in critically ill patients. *Crit Care Med* 1999, **27**:1794-1799.
22. Kollef MH, Silver P, Murphy DM, Trovillion E: **The effect of late-onset ventilator-associated pneumonia in determining patient mortality.** *Chest* 1995, **108**:1655-1662.
 23. Garrouste-Orgeas M, Marie O, Rouveau M, Villiers S, Arlet G, Schlemmer B: **Secondary carriage with multi-resistant *Acinetobacter baumannii* and *Klebsiella pneumoniae* in an adult ICU population: relationship with nosocomial infections and mortality.** *J Hosp Infect* 1996, **34**:279-289.
 24. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H: **Nosocomial bloodstream infections caused by *Acinetobacter* species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility.** *Clin Infect Dis* 2000, **31**:690-697.
 25. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, Aldabo-Pallas T, Cayuela A, Marquez-Vacaro JA, Garcia-Curiel A, Jimenez-Jimenez FJ: ***Acinetobacter baumannii* ventilator-associated pneumonia: epidemiological and clinical findings.** *Intensive Care Med* 2005, **31**:649-655.
 26. Sofianou DC, Constandinidis TC, Yannacou M, Anastasiou H, Sofianos E: **Analysis of risk factors for ventilator-associated pneumonia in a multidisciplinary intensive care unit.** *Eur J Clin Microbiol Infect Dis* 2000, **19**:460-463.
 27. Vahaboglu H, Coskuncan F, Tansel O, Ozturk R, Sahin N, Koksali, Kocazeybek B, Tatman-Otkun M, Leblebicioglu H, Ozinel MA, et al.: **Clinical importance of extended-spectrum β -lactamase (PER-1-type)-producing *Acinetobacter* spp. and *Pseudomonas aeruginosa* strains.** *J Med Microbiol* 2001, **50**:642-645.
 28. Salas Coronas J, Cabezas Fernandez T, Alvarez-Ossorio Garcia de Soria R, Rogado Gonzalez MC, Delgado Fernandez M, Diez Garcia F: **Nosocomial infection/colonization of the respiratory tract caused by *Acinetobacter baumannii* in an internal medicine ward. [In Spanish].** *An Med Interna* 2002, **19**:511-514.
 29. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegmanglra Y, Carmeli Y: **Multidrug-resistant *Acinetobacter baumannii*.** *Emerg Infect Dis* 2005, **11**:22-29.
 30. del Mar Tomas M, Cartelle M, Pertega S, Beceiro A, Llinares P, Canle D, Molina F, Villanueva R, Cisneros JM, Bou G: **Hospital outbreak caused by a carbapenem-resistant strain of *Acinetobacter baumannii*: patient prognosis and risk-factors for colonisation and infection.** *Clin Microbiol Infect* 2005, **11**:540-546.
 31. Krcmery V Jr, Spanik S, Krupova I, Trupl J, Kunova A, Smid M, Pichnova E: **Bacteremia due to multiresistant gram-negative bacilli in neutropenic cancer patients: a case controlled study.** *J Chemother* 1998, **10**:320-325.
 32. Maragakis LL, Cosgrove SE, Song X, Kim D, Rosenbaum P, Ciesla N, Srinivasan A, Ross T, Carroll K, Perl TM: **An outbreak of multidrug-resistant *Acinetobacter baumannii* associated with pulsatile lavage wound treatment.** *JAMA* 2004, **292**:3006-3011.